Biomarker predicts outcome for prostate cancer:
This article was originally published in Clinica
Executive Summary
The biomarker Ki-67 has emerged as a strong predictor of death from prostate cancer following radiotherapy, according to what is claimed to be the largest known study of its type. Ki-67 is involved in tumour proliferation. A team from the Fox Chase Cancer Center in Salt Lake City, Utah, performed immunohistochemical staining for Ki-67 on tissue samples from 537 patients who has undergone radiation therapy. It found that the higher the amount of Ki-67, the greater the risk the cancer would spread. The findings were reported at the this month's American Society for Therapeutic Radiology and Oncology meeting in Salt Lake City.